Long-Term Consequences of Worsened Poststroke Status in Patients With Premorbid Disability

Background and Purpose— Patients with premorbid disability, generally defined as modified Rankin Scale (mRS) score ≥2, are often excluded from trials of acute stroke therapies. However, increased disability in such patients will adversely affect long-term outcomes if treatments are withheld in routine practice. We assessed the extent to which increased disability poststroke influences 5-year mortality, institutionalization, and costs in premorbidly disabled patients. Methods— In a population-based, prospective cohort of patients with ischemic stroke (OXVASC [Oxford Vascular Study], 2002–2014), we tracked mortality, institutionalization, and healthcare/social-care costs during follow-up. We compared 5-year mortality and poststroke institutionalization (Cox regressions) and 5-year healthcare/social-care costs (generalized linear model) in 3-month survivors with premorbid mRS of 2 to 4 (excluding extreme disability, mRS=5), based on the degree of change in mRS(&Dgr;mRS) from prestroke to 3 months poststroke, adjusting analyses for age/sex/initial National Institutes of Health Stroke Scale. Results— Among 1607 patients, 530 (33.0%) had premorbid mRS of 2 to 4. Only 2 premorbidly disabled patients received thrombolysis, but 421 (79.4%) were alive at 3 months. &Dgr;mRS was independently associated with 5-year mortality/institutionalization (adjusted hazard ratio for &Dgr;mRS=1 versus 0: 1.59; 95% CI, 1.20–2.11; &Dgr;mRS=2: 2.39; 95% CI, 1.62–3.53; &Dgr;mRS=3: 4.12; 95% CI, 1.98–8.60; P<0.001) and costs (margin for &Dgr;mRS ≥2 versus 0: $30 011, 95% CI, $4222–55 801; P=0.023). Results were similar on examining patients with premorbid mRS of 2, 3, and 4 separately (eg, 5-year mortality/institutionalization adjusted hazard ratio for premorbid mRS=3 with &Dgr;mRS=1 versus 0: 1.60; 95% CI, 1.06–2.42; P=0.027; &Dgr;mRS=2: 3.20; 95% CI, 1.85–5.54; P<0.001). Conclusions— Patients with stroke with premorbid disability have higher mortality, institutionalization, and costs if they accumulate additional disability because of the stroke. These findings highlight the long-term outcomes expected if acute interventions are routinely withheld in patients with mild-moderate premorbid disability and suggest that trials/registries should include such patients.

[1]  W. Powers,et al.  2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2018, Stroke.

[2]  E. Warburton,et al.  Pre-Stroke Modified Rankin Scale: Evaluation of Validity, Prognostic Accuracy, and Association with Treatment , 2017, Front. Neurol..

[3]  S. Gutnikov,et al.  Time Course of Evolution of Disability and Cause‐Specific Mortality After Ischemic Stroke: Implications for Trial Design , 2017, Journal of the American Heart Association.

[4]  P. Bovi,et al.  Reasons for exclusion from intravenous thrombolysis in stroke patients admitted to the Stroke Unit , 2016, Journal of Thrombosis and Thrombolysis.

[5]  M. Mazighi,et al.  European Recommendations on Organisation of Interventional Care in Acute Stroke (EROICAS) , 2016, International journal of stroke : official journal of the International Stroke Society.

[6]  M. Mazighi,et al.  European recommendations on organisation of interventional care in acute stroke (EROICAS) , 2016, European stroke journal.

[7]  A. Demchuk,et al.  Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials , 2016, The Lancet.

[8]  C. Nolte,et al.  Intravenous Thrombolysis in Patients Dependent on the Daily Help of Others Before Stroke , 2016, Stroke.

[9]  Eric E. Smith,et al.  Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2016, Stroke.

[10]  P. Langhorne,et al.  Derivation and Validation of a Novel Prognostic Scale (Modified–Stroke Subtype, Oxfordshire Community Stroke Project Classification, Age, and Prestroke Modified Rankin) to Predict Early Mortality in Acute Stroke , 2016, Stroke.

[11]  J. Grotta,et al.  Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale , 2015, Stroke.

[12]  P. Sandercock,et al.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .

[13]  R. Cote,et al.  The quality of treatment of hyperacute ischemic stroke in Canada: a retrospective chart audit. , 2014, CMAJ open.

[14]  V. Demarin,et al.  Role of Preexisting Disability in Patients Treated With Intravenous Thrombolysis for Ischemic Stroke , 2014, Stroke.

[15]  B. Kissela,et al.  Distribution of National Institutes of Health Stroke Scale in the Cincinnati/Northern Kentucky Stroke Study , 2013, Stroke.

[16]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[17]  K. McArthur,et al.  Prestroke Modified Rankin Stroke Scale Has Moderate Interobserver Reliability and Validity in an Acute Stroke Setting , 2012, Stroke.

[18]  P. Rothwell,et al.  A Population-Based Study of Hospital Care Costs During 5 Years After Transient Ischemic Attack and Stroke , 2012, Stroke.

[19]  M. O’Donnell,et al.  The PLAN score: a bedside prediction rule for death and severe disability following acute ischemic stroke. , 2012, Archives of Internal Medicine.

[20]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[21]  P. Rochon,et al.  Is pre-existing dementia an independent predictor of outcome after stroke? A propensity score-matched analysis , 2012, Journal of Neurology.

[22]  J. Potter,et al.  Association Between Prestroke Disability and Inpatient Mortality and Length of Acute Hospital Stay After Acute Stroke , 2012, Journal of the American Geriatrics Society.

[23]  A. Alshekhlee,et al.  Does dementia increase risk of thrombolysis? , 2011, Neurology.

[24]  V. Feigin,et al.  Auckland Stroke Outcomes Study , 2010, Neurology.

[25]  Elsa Azevedo,et al.  Intravenous Alteplase for Stroke in Those Older Than 80 Years Old , 2010, Stroke.

[26]  M. Walters,et al.  Variability in Modified Rankin Scoring Across a Large Cohort of International Observers , 2008, Stroke.

[27]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[28]  M. Walters,et al.  Initial Experience of a Digital Training Resource for Modified Rankin Scale Assessment in Clinical Trials , 2007, Stroke.

[29]  S. Gutnikov,et al.  Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) , 2005, The Lancet.

[30]  L. Lisabeth,et al.  Emergency department evaluation of ischemic stroke and TIA , 2004, Neurology.

[31]  P. Rothwell,et al.  Direct Assessment of Completeness of Ascertainment in a Stroke Incidence Study , 2004, Stroke.

[32]  V. Hachinski,et al.  Effects of thrombolysis for acute stroke in patients with pre-existing disability. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[33]  Konrad Jamrozik,et al.  Long-Term Disability After First-Ever Stroke and Related Prognostic Factors in the Perth Community Stroke Study, 1989–1990 , 2002, Stroke.

[34]  E. Feuer,et al.  Estimating medical costs from incomplete follow-up data. , 1997, Biometrics.

[35]  Timothy W. Smith,et al.  INCIDENCE STUDY , 1966, Encyclopedia of Behavioral Medicine.

[36]  OpeoluAdeoye,et al.  Distribution of National Institutes of Health Stroke Scale in the Cincinnati/Northern Kentucky Stroke Study , 2013 .

[37]  D. Reker,et al.  Factors associated with VHA costs of care for first 12 months after first stroke. , 2008, Journal of rehabilitation research and development.

[38]  G. Duckwiler,et al.  Intra-arterial thrombolysis for acute stroke in patients 80 and older: a comparison of results in patients younger than 80 years. , 2007, AJNR. American journal of neuroradiology.

[39]  D. Wade,et al.  The Barthel ADL Index: a standard measure of physical disability? , 1988, International disability studies.

[40]  S. Hatano,et al.  Experience from a multicentre stroke register: a preliminary report. , 1976, Bulletin of the World Health Organization.